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Osteoclastsγδ T cells, a small subset of T cell population (5–10%), forms a bridge between innate and adaptive immunity. Al-
though the role of γδ T cells in infectious diseases and antitumor immunity iswell investigated, their role in bone
biology needs to be explored. Aminobisphosphonates are used as a standard treatmentmodality for bone related
disorders and are potent activators of γδ T cells. In the present study, we have compared the effect of “activated”
and “freshly isolated” γδ T cells on osteoclast generation and function. We have shown that “activated” (αCD3/
CD28 + rhIL2 or BrHPP + rhIL2 stimulated) γδ T cells inhibit osteoclastogenesis, while “freshly isolated” γδ T
cells enhance osteoclast generation and function. Upon stimulation with phosphoantigen (BrHPP), “freshly iso-
lated” γδ T cells were also able to suppress osteoclast generation and function. Cytokine proﬁles of these cells re-
vealed that, “freshly isolated” γδ T cells secrete higher amounts of IL6 (pro-osteoclastogenic), while “activated”
γδ T cells secrete high IFNγ levels (anti-osteoclastogenic). Neutralization of IFNγ and IL6 reversed the “inhibito-
ry” or “stimulatory” effect of γδ T cells on osteoclastogenesis. In conclusion,we have shown that, activation status
and dynamics of IL6 and IFNγ secretion dictate pro and anti-osteoclastogenic role of γδ T cells.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
γδ T cells represent a unique subset of immune cells accounting for
5–10% of total T cell population in peripheral blood of humans. γδ T
cells are unique as compared to αβ T cells due to their T-cell receptor
(TCR) gene usage, tissue tropism and MHC independent antigen recog-
nition (Chiplunkar et al., 2009; Hayday, 2000). Major subtype of γδ T
cells in human peripheral blood express Vγ9Vδ2 TCR (also called as
Vγ2Vδ2) and are typically of Th1 type secreting copious amount of
IFNγ upon stimulation (Caccamo et al., 2013; Beetz et al., 2007). Similar
to αβ T cells, γδ T cells exhibit plasticity and can differentiate into Th2
(Wesch et al., 2001; Sireci et al., 1997), Th17 (Ness-Schwickerath
et al., 2010; Caccamo et al., 2011), Tfh (Caccamo et al., 2013) and Tcells; FH, Ficoll-Hypaque; RPMI,
ohydrin pyrophosphate; OPCs,
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. This is an open access article underregulatory (Casetti et al., 2009) type. γδ T cells play an important role
in antitumor cytotoxicity (Konigshofer and Chien, 2006; Kabelitz et al.,
2013), wound healing and tissue repair (Sharp et al., 2005; Jameson
et al., 2005; Havran et al., 2005). These cells express natural killer recep-
tors (Born et al., 2006; Hayday, 2009) and recognize stressed/tumour
cells expressing MICA/B and ULBPs (Wu et al., 2014). γδ T cells are in-
creased in bacterial, viral and parasitic infections (Born et al., 2006). An-
titumor ability of γδ T cells against solid tumours and leukaemia's has
been widely reported (Wrobel et al., 2007; Todaro et al., 2009; Gomes
et al., 2010; Gertner-Dardenne et al., 2012; Dhar and Chiplunkar,
2010; Thomas et al., 2000; Laad et al., 1999). A unique set of antigens
recognized by γδ T cells include intermediate products of eukaryotic
mevalonate pathway (isopentenyl pyrophosphate or its synthetic ana-
logue bromohydrin pyrophosphate) and bacterial Rohmer pathway
(HMBPP [(E)-4-hydroxy-3-methyl-but-2-enylpyrophosphate]). Plant
derived alkylamines and aminobisphosphonates are also known to
activate γδ T cells (Born et al., 2006). Aminobisphosphonates and anti-
RANKL therapies are used to treat patients with bone metastasis to
reduce the skeletal complications and tumour burden (Lipton and
Goessl, 2011; Roodman and Dougall, 2008; Lee et al., 2011a;
Neville-Webbe and Coleman, 2010). The meta-analysis done to analyse
the safety and efﬁcacy of Vγ9Vδ2 based immunotherapy has shown im-
proved overall survival in patients compared to conventional therapies
(Buccheri et al., 2014).
Though bone appears to be static in nature, it is a dynamic structure
which undergoes continuous remodelling. The process of bonethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Osteoblasts are derived from mesenchymal cells, secrete bone matrix
proteins and promote mineralization. Osteoclasts are large multinucle-
ated cells generated by fusion of monocyte-macrophage precursor
cells (Soysa et al., 2012) and are known to decalcify and degrade the
bone by secreting the lysosomal proteases (Teitelbaum, 2007). In nor-
mal conditions, osteoclasts and osteoblastswork in coordinatedmanner
to maintain normal bone physiology, while their imbalance results in
pathological conditions, such as osteoporosis, rheumatoid arthritis
(RA), Paget's disease and osteopetrosis. Immune system and skeletal
system are inﬂuenced by a number of common cytokines, chemokines,
signalling molecules and transcription factors (Takayanagi, 2007). Acti-
vated T lymphocytes support osteoclastogenesis through production of
IL6 (Kurihara et al., 1990), IL17 (Sato et al., 2006), RANKL (Horwood
et al., 1999; Weitzmann et al., 2001; Takayanagi et al., 2000) and
TNFα (Lam et al., 2000). Inﬂamed synovial joints of rheumatoid arthritic
patients showed presence of γδ T cells (Keystone et al., 1991), though
γδ T cells were not recognized as major contributors of arthritic bone
destruction (Pollinger et al., 2011). It was recently demonstrated that
activated γδ T cells inhibit osteoclast differentiation and their resorptive
function hence have important implications in understanding
pathogenesis of rheumatoid arthritis (Pappalardo and Thompson,
2013). In disease free breast cancer patients, a single dose of
aminobisphosphonate (zoledronic acid) induces a long lasting activa-
tion of effector subsets of γδ T cells (Santini et al., 2009). These studies
indicate that activation status of γδ T cells is responsible for their
antiosteoclastogenic activity. The objective of the present study was to
have a comparative analysis of “activated” and “freshly isolated” γδ T
cells with respect to their effect on generation and function of osteo-
clasts. Our results demonstrate that “activated” γδ T cells inhibit gener-
ation and resorptive ability of osteoclasts, while “freshly isolated” γδ T
cells promote osteoclast formation and function.
2. Materials and methods
2.1. Study group
Peripheral blood from healthy volunteers (age, 25–45 years) was
collected in heparin containing vacutainers. The present study was ap-
proved by the Institutional Ethics Committee and informed consents
were taken from the healthy volunteers before collecting the blood
sample.
2.2. Expansion and isolation of γδ T cells
γδ T cells were either directly isolated from peripheral blood mono-
nuclear cells (PBMCs) or from ex-vivo expanded PBMC cultures. Brieﬂy,
PBMCs were separated from heparinised peripheral blood of healthy
individuals by Ficoll-Hypaque (Sigma-Aldrich, USA) density gradient
centrifugation. PBMCs (5 × 106), resuspended in 5 ml cRPMI (10%
heat-inactivated human AB serum, 2 mM glutamine, and antibiotics)
were stimulated for 12 days with rhIL-2 (30 IU/ml) in 25 mm2 tissue
culture ﬂasks precoated with αCD3 (1 μg) + αCD28 (1 μg), with
intermediate feedings with rhIL2. These cells were subcultured after
6 days. On the 12th day, cultures were terminated and γδ T cells were
immunomagnetically separated (positive selection) by using γδ-TCR
MACS kit (magnetic activated cell sorting, Milteney Biotech, Germany)
as per the kit instructions. On the 12th day, 13 ± 2.5 × 106 γδ T cells
were obtained from αCD3/CD28 expanded PBMCs (150 ± 40 × 106).
“Freshly isolated” γδ T cells were obtained from PBMCs without expan-
sion. About 3.8± 1.6 × 106 γδ T cells were isolated directly from PBMCs
(130±52× 106) byMACS puriﬁcation. The purity of theMACS separat-
ed γδ T cells (FITC labelled)was analysed by ﬂow cytometry and ranged
from 95 to 98%. The γδ T cells were rested overnight in medium before
using them for further experiments. γδ T cells puriﬁed from αCD3/
CD28 + rhIL2 expanded PBMCs are termed as “activated” γδ T cells,while γδ T cells isolated directly from PBMCs are referred as “freshly
isolated” γδ T cells.
2.3. Flow cytometry
Expression of CD69, CD25 and RANKL was analysed on “activated”
and “freshly isolated” γδ T cells. To analyse expression of CD69, CD25
and RANKL on “activated” γδ T cells, PBMCs (1 × 106/ml) were cultured
in cRPMI supplemented with either rhIL2 (30 IU/ml) alone, BrHPP
(200 nM) + rhIL2 or αCD3/CD28 (1 μg) + rhIL2 for 12 days in 24
well plate at 37 °C in 5% CO2 incubator. BrHPP is a synthetic analogue
of isopentenyl pyrophosphate (Espinosa et al., 2001) and is used as an-
tigen for γδ T cells. The cells were fed with rhIL2 every 3rd day and
subcultured on the 6th day. PBMCs without any stimulation (Day
0) were kept as control. On termination of culture on the 12th day, ex-
panded PBMCs were collected, washed in cold 1× PBS (4 °C) and resus-
pended in cold FACS buffer (1× PBS, 2% FCS, 0.01% sodium azide) as
1 × 106 PBMCs/50 μl. These PBMCs were then stained for markers like
γδ-TCR-APC (BD Pharmingen, USA), CD25-PECy7 (BD Pharmingen,
USA), CD69-FITC (BD Pharmingen, USA), RANKL-PE (Biolegend, USA)
at 4 °C for 30 min in dark, followed by ﬁxing in 1% paraformaldehyde
at 4 °C for 15 min in dark. For “freshly isolated” γδ T cells (directly sep-
arated from PBMCs on Day 0), puriﬁed γδ T cells were rested overnight
and then were stimulated either with rhIL2 (0.5 IU) alone, αCD3/CD28
(1 μg) + rhIL2, BrHPP (200 nM) + rhIL2 or left unstimulated (control)
for 24 h at 37 °C in 5% CO2 incubator. 50,000 events were acquired on a
FACS Aria (Becton Dickinson, USA) ﬂow cytometer and data was
analysed using FlowJo Software (Version 10, Tree Star, USA). For the
above experiments, lymphocytes were gated on the basis of their for-
ward and side scatter. Further γδ T cells were gated on the basis of the
ﬂuorescence intensity versus forward scatter and expression of CD69,
CD25 and RANKL was analysed on the gated γδ T cell population.
2.4. Cytometric bead array
“Activated” (separated from αCD3/CD28 expanded PBMCs) and
“freshly isolated” γδ T cells (5 × 104), resuspended in cRPMI (200 μl),
were stimulated with rhIL2 (0.5 IU) alone or BrHPP (200 nM) + rhIL2
(0.5 IU), in round bottom 96 well plate (Nunc) for 24 h at 37 °C in 5%
CO2 incubator. The experimental groups were as represented below
(Groups 1 to 4).
After 24 h, cells free supernatants from Groups 1–4 were collected
and were stored at−80 °C. As experimental controls, cell free superna-
tantswere collected from “activated” and “freshly isolated” γδ T cells in-
cubated in medium only (unstimulated) for 24 h. Th1/Th2/Th17
cytokines (IL2, IL4, IL6, IL10, TNFα, IFNγ and IL17A) in these superna-
tants were analysed using cytometric bead array kit (BD Biosciences)
as per the kit instructions. In brief, 50 μl test samples and PE detection
antibody were incubated with capture bead reagent for 3 h at room
temperature in dark, followed by washing with wash buffer. Samples
were acquired on BD FACS Aria cytometer (BD Bioscience, San Jose,
CA, USA) and data was analyzed using FCAP Array software version
1.0 (BD Biosciences).
2.5. Generation of human osteoclasts
Human osteoclasts were generated from CD14+ cells (monocytes)
in the presence of rhMCSF and rhRANKL (Gupta et al., 2010). In brief,
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method using CD14 MACS kit (Milteney Biotech). CD14+ cells
(1 × 105) were cultured on thermanox coverslips (Nunc) in ﬂat bottom
96 well plate containing 200 μl cαMEM (10% heat inactivated FCS
(Invitrogen Life Technologies, USA), 2 mM L-glutamine and antibiotics)
at 37 °C in 5% CO2 incubator. These cultures were supplemented with
30 ng/ml rhMCSF (R&D Systems) and 40 ng/ml rhRANKL (R&D Sys-
tems) and were replenished on every 3rd day. On the 21st day, mature
multinucleated osteoclasts were characterized by staining for expres-
sion of vitronectin receptor (αVβ3 integrin) usingmonoclonal antibody
for CD51/61 (Biolegend), also known as 23c6 antibody along with
nuclear stain DAPI. 23c6+ cells having N3 nuclei were considered as
mature osteoclasts (Supplementary Fig. 1A).
2.6. CD14+ and γδ T cell coculture assay
Effect of γδ T cells on osteoclastogenesis was analysed by generating
osteoclasts from CD14+ cells in the presence of autologous “activated”
(ACT) or “freshly isolated” (FI) γδ T cells. On Day 0, CD14+ cells
(1 × 105) were cocultured with unstimulated “activated” or “freshly
isolated” γδ T cells (1 × 104) in cαMEM (200 μl) containing rhMCSF
(30 ng/ml), rhRANKL (40 ng/ml) and rhIL2 (0.5 IU). As a positive con-
trol, osteoclasts were generated from CD14+ cells in the presence of
rhMCSF and rhRANKL only. To analyse the effect of phosphoantigen
stimulated “freshly isolated” γδ T cells on osteoclastogenesis, BrHPP
(200 nM) was also added to cocultures along with rhMCSF and
rhRANKL on Day 0. For 21 days, CD14: γδ T cells (10:1) were nourished
with rhMCSF, rhRANKL and rhIL2 on every 3rd day. On the 21st day,
multinucleated (N3 nuclei) 23c6+ osteoclasts generated in an entire
well were quantiﬁed and the effect of γδ T cells on osteoclastogenesis
was determined by analysing increase or decrease in the total number
of osteoclast generated per well as compared to control wells.
2.7. In vitro bone resorption assay using osteoclast activity assay substrate
(OAAS)
“Activated” and “freshly isolated” γδ T cells were stimulated with
rhIL2 or BrHPP+ rhIL2 for 24 h and cell free supernatants were collect-
ed (Groups 1–4) as described above (Section 2.4). Osteoclast precursor
cells were generated from CD14+ cells (1 × 105) in the presence of
rhMCSF and rhRANKL for 12 days in OAAS module (BD Biosciences).
OAAS is a 16 well module, with thin calcium-phosphate coated wells
and is used to evaluate functional activity of osteoclasts in vitro. From
the 12th day onwards, every 3rd day, the cultures were supplemented
with pretitrated volumes of cell free supernatant (50 μl) from Groups
1–4 alongwith rhMCSF and rhRANKL. Osteoclasts generated in thepres-
ence of rhMCSF and rhRANKL were kept as positive control. On the 21st
day, the cells were bleached out using 6% sodium hypochlorite and 5.2%
sodium chloride. OAAS plates were air dried and resorption area/pits
generated bymature resorbing osteoclasts were imaged using light mi-
croscopy (Supplementary Fig. 1B). The resorptive ability of osteoclasts
was assessed by quantifying the total resorbed area generated in
OAAS well using ImageJ Software.
2.8. Cytokine neutralization
Osteoclast precursor cells were generated from CD14+ cells
(1 × 105) in the presence of rhMCSF and rhRANKL for 12 days in
OAAS module as described above. From the 12th day onwards, every
3rd day, along with rhMCSF and rhRANKL, the cultures were supple-
mented with 50 μl cell free supernatant of unstimulated “activated”
and “freshly isolated” γδ T cells, with or withoutmonoclonal mouse an-
tihumanαIFNγ orαIL6 neutralization antibody (10 μg/ml/well) respec-
tively. Osteoclasts generated in the presence of rhMCSF and rhRANKL
were kept as positive control. On the 21st day, the cultures were termi-
nated and resorption area was calculated using ImageJ software.2.9. Statistical analysis
Thedatawas analysed using student's unpaired t test. p values ≤ 0.05
were considered statistically signiﬁcant [p b 0.05 (*), p b 0.005 (**),
p b 0.0005 (***)]. Error bar indicates mean ± SEM.
3. Results
3.1. Expression of activationmarkers (CD69, CD25 and RANKL) onγδ T cells
Expression of activation markers (CD69, CD25 and RANKL) on γδ T
cells were analysed by stimulating these cells with two distinct TCR
signals (αCD3/CD28 or BrHPP) in the presence of rhIL2.
As shown in Fig. 1A, unstimulated PBMCs (Day 0) showed lower ex-
pression levels of CD69 (3.62% [percent positive], MFI = 72.5[mean
ﬂuorescent intensity]), CD25 (16.2%, MFI = 405) and RANKL (4.06%,
MFI = 115) on gated γδ T cells. However, a marked increase in expres-
sion of CD25 and RANKL was observed on γδ T cells upon stimulation
of PBMCs with αCD3/CD28 + rhIL2 (100%, MFI = 134,379 and 53.5%,
MFI = 641 respectively) or BrHPP + rhIL2 (99.1%, MFI = 17,740
and 36.4%, MFI = 654 respectively) for 12 days. Almost all γδ T cells
were positive for CD25 expression after stimulation, indicating that
these cells were in highly activated state. Expression of CD69 (early
activation marker) on γδ T cells was found marginal changed upon
stimulation of PBMCs with αCD3/CD28 + rhIL2 (0.9%, MFI =−714)
and BrHPP + rhIL2 (2.82%, MFI = 211) for 12 days compared to
unstimulated PBMCs (3.62%, MFI = 72.5).
Expression of these activation markers were also analysed on
immunomagnetically puriﬁed γδ T cells (Fig. 1B). Puriﬁed (“freshly iso-
lated”) γδ T cells were either left unstimulated (control) or were stimu-
lated with rhIL2 alone or a combination of αCD3/CD28 + rhIL2 or
BrHPP + rhIL2 for 24 h. As shown in Fig. 1B, in an unstimulated state,
“freshly isolated” γδ T cells showed lower levels of CD69 (5.04%,
MFI = 126), CD25 (2.48%, MFI = 103) and RANKL (1.72%, MFI =
41.4). Upon stimulation with rhIL2 for 24 h, increase in the expression
of CD69 (29.2%, MFI = 295), CD25 (9.10% MFI = 354) and RANKL
(3.79%MFI= 81.3)was observed. “Freshly isolated” γδ T cells stimulat-
edwithαCD3/CD28+ rhIL2 or BrHPP+ rhIL2 showedmarkedly higher
levels of CD69 (39.8%, MFI = 344 and 52.4%, MFI = 335 respectively),
CD25 (13.2%, MFI = 512 and 18.3%, MFI = 677 respectively) and
RANKL (7.38%, MFI = 106 and 9.49%, MFI = 77.6 respectively) as com-
pared to unstimulated and rhIL2 stimulated γδ T cells. Thus on the basis
of expression of activation markers (CD69, CD25 and RANKL) γδ T cells
were considered as “non-activated” (freshly isolated) and “activated”
(isolated from αCD3/CD28 + rhIL2 stimulated PBMCs) γδ T cells.
3.2. Direct effect of γδ T cells on generation of osteoclast
CD14+ cells (1 × 105/well, osteoclast precursor cells) were
cocultured with “activated” or “freshly isolated” γδ T cells (1 × 104/
well,10:1) in the presence of rhMCSF, rhRANKL and rhIL2 for 21 days
(described in material and methods Section 2.6), with intermediate
feedings on every 3rd day. Osteoclasts generated in the presence of
rhMCSF and rhRANKL served as a positive control. Osteoclasts showing
multinucleation (≥3 nuclei) and 23c6 positivity (vitronectin receptor)
were considered as mature osteoclasts. Number of osteoclasts generat-
ed (25 ± 4 osteoclasts/well) in the presence of rhMCSF and rhRANKL
(positive control) were normalized to 100% and data has been repre-
sented as relative increase or decrease in number of osteoclasts generat-
ed per well compared to positive control. Coculture of “activated” γδ T
cells with CD14+ cells in the presence of rhMCSF and rhRANKL showed
signiﬁcant reduction (1.5 ± 0.5 osteoclasts/well, 93.6% reduction, p =
0.0012) in 23c6+ multinucleated osteoclasts compared to positive con-
trol (Fig. 2). In contrast, generation of osteoclasts in the presence of
“freshly isolated” γδ T cells showed marked increase in the number of
23c6+ multinucleated osteoclasts (53.5 ± 14.5 osteoclasts/well, 110%
Fig. 1. Analysis of activation markers (CD69, CD25, and RANKL) on γδ T cells. A) Expression of activation markers (CD69, CD25, and RANKL) was analysed on γδ T cells in unstimulated
PBMCs (1 × 106/ml/well) or PBMCs expanded with rhIL2 (30 IU/ml) alone, αCD3/CD28 (1 μg) + rhIL2 or BrHPP (200 nM) + rhIL2 for 12 days. After the 12th day, PBMCs were stained
usingγδ-APC, CD69-FITC, CD25-PeCy7, andRANKL-PE. Baseline expression of thesemakers onγδT cellswas analysed by staining unstimulated PBMCs (Day 0, control). The gating strategy
usedwas as follows: Lymphocyteswere gated based on their forward and side scatter. Depending on theﬂuorescence intensity ofγδ-APC,γδ T cellswere gated. Further percentages ofγδT
cells expressing CD69, CD25 and RANKLwere analysed on gatedγδ T cells. The gates have been set according to only cell controls for respective stimulation.B) Puriﬁedγδ T cells were also
stimulated with rhIL2 alone, αCD3/CD28 + rhIL2 or BrHPP + rhIL2 for 24 h or left unstimulated (medium alone) and were analysed for the expression of CD69, CD25 and RANKL. The
gating strategy used was as described above. (Three independent experiments were carried out and the representative ﬁgure is given.)
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Fig. 2. Effect of “activated” and “freshly isolated” γδ T cells on generation of osteoclasts.
CD14+ cells (1 × 105/well) were co-cultured with “activated” (ACT) or “freshly isolated”
(FI) γδ T cells (1 × 104) in cαMEM supplemented with rhMCSF (30 ng/ml), rhRANKL
(40 ng/ml) and rhIL2 (0.5 IU/well) on thermanox coverslips (Nunc) in ﬂat bottom 96
well plate. Osteoclasts generated in the presence of rhMCSF and rhRANKL were kept as
positive control. “Freshly isolated” γδ T cells were stimulated with phosphoantigen by
supplementing the cultures with BrHPP (200 nM) along with rhMCSF, rhRANKL and
rhIL2 on Day 0. The CD14+: γδ T cell cocultures were fed with rhMCSF, rhRANKL, rhIL2
every 3rd day for 21 days. On the 21st day, osteoclasts were characterized by staining
them for vitronectin receptor (anti-human-CD51/CD61-AF488) and total number of
osteoclasts (multinucleated 23c6+ cells) generated per well were quantitated. Number
of osteoclasts generated in the presence of rhMCSF and rhRANKL (positive control) were
normalized to 100% and data has been represented as relative increase or decrease
in number of osteoclasts generated per well compared to positive control. Three indepen-
dent experiments were carried out and the data is represented as mean ± SEM.
[p b 0.05 (*), p b 0.005 (**), p b 0.0005 (***)].
Fig. 3. Effect of supernatants of γδ T cells on resorptive ability of osteoclasts. Osteoclasts
were generated from CD14+ cells (1 × 105/well) in the presence of rhMCSF (30 ng/ml)
and rhRANKL (40 ng/ml) for 12 days on osteoclast activity assay substrate. From
the 12th day onwards, the cultures were fed with cell free supernatants of “activated”
and “freshly isolated” γδ T cells, stimulated with rhIL2 (Group 1 and Group 3) or
BrHPP + rhIL2 (Group 2 and Group 4) respectively, along with rhMCSF and rhRANKL on
every 3rd day. Osteoclasts generated in the presence of rhMCSF and rhRANKL were kept
as positive control. The cultures were terminated on the 21st day and the area resorbed
by mature osteoclasts was calculated using ImageJ software. Total resorption area gener-
ated per well by osteoclasts cultured in the presence of rhMCSF and rhRANKL (positive
control) was normalized to 100% and data has been represented as relative increase or
decrease in resorption area compared to positive control. The data shown is mean ±
SEM of three independent experiments. [p b 0.05 (*), p b 0.005 (**), p b 0.0005 (***)].
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inhibit osteoclastogenesis, while “freshly isolated” γδ T cells tend to in-
crease the number of osteoclasts upon coculture. In order to conﬁrm
this observation “freshly isolated” γδ T cells were cocultured with
CD14+ cells in the presence of phosphoantigen BrHPP along with
rhMCSF, rhRANKL and rhIL2. It was interesting to observe that genera-
tion of osteoclasts in the presence of “freshly isolated” γδ T cells that
were stimulatedwith BrHPP showed signiﬁcant reduction (2.5±1.5 os-
teoclasts/well, 88.8% reduction, p = 0.0078) in the total number of
23c6+ osteoclasts, conﬁrming that “activation status” of γδ T cells gov-
ern their function to regulate osteoclastogenesis. CD14+ cells cultured
in the presence of rhMCSF and rhRANKL in the presence of rhIL2
(26.5 ± 3.5 osteoclasts/well) or BrHPP+ rhIL2 (28 ± 3 osteoclasts/
well) showed osteoclast numbers that were comparable to that ob-
served in positive control (25 ± 4 osteoclasts/well), indicating that
rhIL2 or BrHPP + rhIL2 had no effect on osteoclast generation.
3.3. Effect of soluble factors secreted by phosphoantigen stimulated γδ T
cells on function of osteoclasts
In order to investigate the indirect effect of γδ T cells on osteoclast
function mediated through secretion of soluble factors upon
phosphoantigenic stimuli, osteoclast precursor cells (OPCs, generated
on OAAS using rhMCSF and rhRANKL for 12 days) were cultured in
the presence of pretitrated volumes of cell free supernatants of “activat-
ed” and “freshly isolated” γδ T cells, stimulated with rhIL2 or
BrHPP + rhIL2 (Groups 1–4), along with rhMCSF and rhRANKL. Osteo-
clasts cultured in the presence of rhMCSF and rhRANKL were kept as
positive control. Total resorbed area generated by resorbing osteoclastsin OAASwellwas used as end pointmeasurement of assay. Total resorp-
tion area generated per well by osteoclasts cultured in the presence of
rhMCSF and rhRANKL (positive control) was normalized to 100% and
data has been represented as relative increase or decrease in resorption
area compared to positive control. As shown in Fig. 3, OPCs, supple-
mented with supernatants of “activated” γδ T cells which were stimu-
lated with rhIL2 alone (Group 1) or BrHPP + rhIL2 (Group 2) showed
72% and 70.4% reduction (p = 0.0001 and p = 0.0011 respectively) in
the total resorbed area as compared to positive control. Similarly, effect
of soluble factors secreted by “freshly isolated” γδ T cells which were
stimulated with rhIL2 alone (Group 3) or BrHPP + rhIL2 (Group 4) on
osteoclast function showed signiﬁcant increase (184.1%, p = 0.002
and 42.6%, p = 0.0192 respectively) in total resorbed area as compared
to positive control. The results clearly indicated that soluble factors se-
creted by “activated” γδ T cells potentially suppress osteoclastmediated
bone resorption, whereas soluble factors secreted by “freshly isolated”
γδ T cells increase bone resorption.
3.4. Cytokine proﬁling of supernatants of antigen activated γδ T cells
Cell free supernatants were collected from “activated” (ACT) and
“freshly isolated” (FI) γδ T cells. The various groups are described inma-
terials and methods, Section 2.4. “Activated” and “freshly isolated” γδ T
cells were either left unstimulated (mediumonly control) or were stim-
ulated with rhIL2 alone (Group 1, Group 3), BrHPP + rhIL2 (Group 2,
Group 4). Cell free supernatants of these cells were collected and
analysed for Th1/Th2/Th17 cytokines by CBA, as represented in Supple-
mentary data, Table 1. Analysis of cell free supernatants of “activated”
and “freshly isolated” γδ T cells in the unstimulated control group inter-
estingly showed signiﬁcant differences in levels of two cytokines- IL6
(pro-osteoclastogenic) and IFNγ (anti-osteoclastogenic) compared to
other cytokines (Supplementary data, Table 1). As shown in Fig. 4, in
Fig. 4. Estimation of IL6 and IFNγ levels in cell free supernatants of “activated” (ACT) and “freshly isolated” (FI)γδ T cells. “Activated” (puriﬁed fromαCD3/CD28+ rhIL2 expandedPBMCs)
or “freshly isolated” (directly puriﬁed from PBMCs on Day 0) γδ T cells (5 × 104/well) were stimulated with rhIL2 (0.5 IU/well) or BrHPP (200 nM) + rhIL2 for 24 h at 37 °C in CO2 incu-
bator. Both “activated” and “freshly isolated” γδ T cells, which were unstimulated (incubated in culture medium alone), were kept as control. After 24 h, the cell free supernatants were
collected. Th1/Th2/Th17 cytokines of these cell free supernatants were quantiﬁed by cytometric bead array (CBA). In an unstimulated state, supernatants of “activated” and “freshly iso-
lated” γδ T cells showedmarked differences in IL6 and IFNγ levels. Stimulation of “activated” and “freshly isolated” γδ T cells with rhIL2 (Group 1, Group 3 respectively) or BrHPP+rhIL2
(Group 2, Group 4 respectively) showed enhanced IFNγ secretion. Levels of IL6 remained higher in cell free supernatants of “freshly isolated” γδ T cells. (“Activated” γδ T cells (n = 5),
“freshly isolated” γδ T cells (n = 7)). [p b 0.05 (*), p b 0.005 (**), p b 0.0005 (***)].
Fig. 5. Effect of IFNγ and IL6 neutralization in cell free supernatants of “activated” (ACT)
and “freshly isolated” (FI)γδ T cells on osteoclast function. CD14+ cells (1× 105)were cul-
tured in the presence of rhMCSF and rhRANKL for 12 days in OAAS module to generate
OPCs. Afterwhich, every 3rd day, the cultureswere supplementedwith 50 μl supernatants
of unstimulated “activated” and “freshly isolated”γδ T cells, rhMCSF, and rhRANKLwith or
without monoclonal mouse αIFNγ or αIL6 neutralization antibody (10 μg/ml/well).
Osteoclasts generated in the presence of rhMCSF and rhRANKL were kept as positive
control. On the 21st day, the cultureswere terminated and resorption areawas calculated.
Resorption area generated in positive control was normalized to 100% and data has been
represented as relative increase or decrease in resorption area compared to positive
control. The data shown is mean ± SEM of two independent experiments. [p b 0.05 (*),
p b 0.005 (**), p b 0.0005 (***)].
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levels of IL6 (Mean ± SEM 2318 ± 471 pg/ml), while “activated”
γδ T cells showed signiﬁcantly (p = 0.005) lower levels of IL6
(1.9 ± 0.3 pg/ml). Comparison of IFNγ levels showed that, “freshly
isolated” γδ T cells secreted very low (3.2 ± 0.27 pg/ml) levels of
IFNγ, while “activated” γδ T cells showed signiﬁcantly (p = 0.008)
higher levels of IFNγ (274.1 ± 111.2 pg/ml).
Upon stimulation with rhIL2, supernatant of “activated” γδ T
cells (Group 1) showed signiﬁcantly higher levels of IFNγ
(706.5 ± 211.8 pg/ml, p = 0.0044) compared to “freshly isolated” γδ
T cells (33.5 ± 29.1 pg/ml, Group 3). Similarly, upon stimulation with
BrHPP + rhIL2, “activated” γδ T cells (Group 2) showed signiﬁcantly
higher levels of IFNγ (879.7 ± 240 pg/ml, p = 0.0264) compared to
“freshly isolated” γδ T cells (260.7 ± 101.2 pg/ml Group 4). Freshly
isolatedγδ T cells upon stimulationwith rhIL2 showed a progressive in-
crease in IFNγ production that further enhanced with BrHPP + rhIL2
stimulation (p = 0.01) compared to unstimulated γδ T cells.
The levels of IL6 secreted by “activated” (Group 1 and Group 3) and
“freshly isolated” (Group 2 and Group 4) γδ T cells were not signiﬁcant-
ly different compared to supernatants of unstimulated γδ T cells
(control).
Results indicate that “freshly isolated”γδ T cells secrete higher levels
of IL6, thus have pro-osteoclastogenic effect, while “activated” γδ T cells
maintain higher levels of IFNγ playing an anti-osteoclastogenic role.
3.5. Effect of IFNγ or IL6 neutralization in cell free supernatants of γδ T cells
on osteoclast function
To validate that the effect ofγδ T cells on osteoclastogenesis is medi-
ated through cytokines (IFNγ and IL6), functional assays were carried
out using neutralizing antibodies to these cytokines. Osteoclasts were
generated in the presence of cell free supernatants of unstimulated “ac-
tivated” and “freshly isolated” γδ T cells in the presence or absence of
αIFNγ or αIL6 antibody. As shown in Fig. 5, osteoclasts generated in
presence of cell free supernatants of “activated” γδ T cells showed sig-
niﬁcant (57.4%) reduction in resorption area (10.78±1 μm2) compared
to positive control (25.4± 0.5 μm2, 100%), After addition ofαIFNγ anti-
body to these cultures the inhibitionwas reversed and brought to 89.7%
(22.7 ± 0.3 μm2), which was comparable to that observed in positive
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ated by “activated” γδ T cells that inhibits osteoclastogenesis.
Similarly, osteoclasts generated in the presence of cell free superna-
tants of “freshly isolated” γδ T cells showed increase in resorption area
by 191.9% (74.1± 1.6 μm2) over positive control (100%). Upon addition
ofαIL6 antibody to the cultures, therewas amarked reduction in the re-
sorption area (34.5 ± 0.2 μm2, p = 0.0068) reducing from 191.9% to
36.1% over positive control (100%).Our results suggests that the dynam-
ics of IFNγ and IL6 play a major role in mediating the pro and anti-
osteoclastogenic effects of “activated” γδ T cells and “freshly isolated”
γδ T cells respectively.
4. Discussion
Bone is a common site of metastasis in breast cancer (Suva et al.,
2009), prostate cancer andmultiplemyeloma (Roodman, 2010).Metas-
tasized tumour cells disturb the bone metabolism by releasing factors
which induce differentiation and activation of osteoclasts (Roodman,
2001). It has also been reported that cytokines secreted by lymphocytes
present in the bone microenvironment affect bone metabolism
(Gillespie, 2007). Investigations are focused on understanding how T
lymphocytes interact with osteoclasts and inﬂuence their function.
Activated CD4+ T cells express RANKL and secrete cytokines such as
IL1β, IL6, IL17, TNFα and RANKL that support osteoclastogenesis
(Horwood et al., 1999; Kotake et al., 2001; Lee et al., 2011b; Kong
et al., 1999). Interestingly, it has also been reported that activated T lym-
phocytes secrete cytokines such as IFNγ, IL4, IL10 andGMCSF that inhib-
it osteoclastogenesis (Walsh et al., 2006; Sato and Takayanagi, 2006). It
is still not understood what dictates the pro and anti-osteoclastogenic
behaviour of the lymphocytes. Although the role of CD4+ αβ T cells in
osteoclastogenesis has been investigated, the role of γδ T cells is not
well understood. In the present study, we have made an attempt to
analyze the effect of “activated” and “freshly isolated” γδ T cells on oste-
oclast generation and function.
We used γδ T cells from two sources; those that were isolated di-
rectly from PBMCs (“freshly isolated” γδ T cells) and those that were
isolated from PBMCs stimulated with αCD3/CD28 + rhIL2 (“activat-
ed” γδ T cells). Coculture of “freshly isolated” γδ T cells with CD14+
cells enhanced the generation of osteoclasts and stimulated their
resorptive ability. On the contrary, “activated” γδ T cells showed inhib-
itory effect on generation and function of osteoclasts. The process of
osteoclastogenesis is majorly inﬂuenced by cytokine milieu in the
microenvironment, where IL6, IL17, TNFα, TGFβ, IFNγ and RANKL
play indispensable role. Analysis of cell free supernatants of “freshly
isolated” γδ T cells at baseline levels (unstimulated) showed marked
difference in their IL6 and IFNγ levels. In an unstimulated state, “freshly
isolated” γδ T cellsweremajor producers of IL6, with negligible levels of
IFNγ. On the contrary, “activated” γδ T cells showed higher IFNγ levels
with low IL6 production.
IL6 is a potent pro-osteoclastogenic cytokine, with the capacity to in-
duce osteoclastogenesis in RANKL independent manner (Kudo et al.,
2003) and it also acts in synergistic manner with TNFα to induce osteo-
clastogenesis (Ragab et al., 2002). IL6 has been reported to stimulate
formation of osteoclast like multinucleated cells in long term cultures
of human bone marrow through induction of IL1β (Kurihara et al.,
1990). T lymphocytes from IL6/ mice have shown lesser production of
IL17 (pro-osteoclastogenic) and also affected RANKL/OPG production
by T lymphocytes (Wong et al., 2006). Cultures of osteoclasts from
bonemarrow cells of IL6/ mice in the presence of MCSF and RANKL pro-
duced ~50% lesser osteoclasts as compared to wild type mice (Wong
et al., 2006). On the contrary, IFNγ has been appreciated for its protec-
tive role in osteoclastogenesis by inhibiting osteoclast formation and
bone resorption in vitro (Takayanagi et al., 2000; Kamolmatyakul
et al., 2001). Mice lacking one of the components of IFNγ receptor
(IFNγR1) showed enhanced osteoclastogenesis from bone marrow de-
rived monocyte/macrophage precursor cells (BMMs) and bone loss(Takayanagi et al., 2000). Also, IFNγ producing activated T cells showed
osteoclast generation from BMMs in the absence of RANKL in IFNγR−/−
mice (Takayanagi et al., 2000). IFNγ either downregulates TRAF6
(TNF receptor associated factor 6) expression or activates/enhances
ubiquitin dependant proteosomal systems whose direct target is
TRAF6 (Takayanagi et al., 2000; Takayanagi et al., 2005), which results
in disruption of RANK–RANKL signalling.
In order to conﬁrm that IL6 and IFNγ are the key cytokines involved
in the pro and anti-osteoclastogenic effects mediated by “freshly isolat-
ed” and “activated” γδ T cells respectively, neutralization experiment
was carried out usingαIL6 andαIFNγ antibodies. Addition ofαIL6 anti-
body to the supernatants of “freshly isolated” γδ T cells showed a
marked reduction in the resorption area. However, the resorption area
remained marginally above that was observed with positive control
(rhMCSF + rhRANKL). The data indicates that other cytokines like
TNFα and IL17 may also contribute to the pro-osteoclastogenic effect,
which may be present in the supernatants after blocking IL6 (Supple-
mentary Table 1). Similarly blocking of IFNγ signiﬁcantly reversed
(89.74%) the anti-osteoclastogenic effect, indicating that IFNγ is the
dominant cytokine inhibiting osteoclastogenesis.
Human γδ T cells are Th1 type cells which produce copious amounts
of IFNγ upon stimulation (Haas et al., 1993; Wang et al., 2001; Garcia
et al., 1997). BrHPP, an analogue of IPP, known to be a potent antigen
of γδ T cells was used to stimulate “freshly isolated” γδ T cells in the
presence of rhIL2. Upon stimulation with BrHPP + rhIL2, the activation
markers (CD69, CD25 and RANKL) on these cells were found to be in-
creased compared to unstimulated γδ T cells. CD69, an early activation
marker, is expressed on T cells upon triggering through TCR complex
(Ziegler et al., 1994). T cell activation through CD69 results in upregula-
tion of CD25 and induction of Th1 cytokine (IL2 and IFNγ), ultimately
triggering proliferation of the lymphocytes (Rutella et al., 1999). As
expected, higher levels of IFNγ along with increased expression of
activation markers (CD25 and RANKL) were observed on “activated”
γδ T cells (which were expanded using αCD3/CD28 + rhIL2), while
no signiﬁcant change was observed in early activation marker CD69.
“Freshly isolated” γδ T cells upon stimulation with BrHPP + rhIL2
showed increase in IFNγ production, along with signiﬁcant increase in
early activation markers like CD69 and RANKL. Compared to rhIL2
stimulated, “freshly isolated” γδ T cells stimulated with BrHPP +
rhIL2, irrespective of short or long term activation, showed inhibitory
effect on generation (vitronectin receptor expression) and resorptive
ability (resorption area on OAAS plates) of osteoclasts. Thus, “freshly
isolated” γδ T cells stimulated with phosphoantigen (BrHPP + rhIL2)
exhibited the characteristics of “activated” γδ T cells to suppress osteo-
clast generation and function.
To best of our knowledge, this is the ﬁrst study to show that activa-
tion status and the cytokines released by γδ T cells dictates their effect
on osteoclastogenesis. Aminobisphosphonates, the new generation
bisphosphonates, are used as standard treatment modality in patients
with breast cancer, prostate cancer and multiple myeloma patients
exhibiting skeletal metastasis (Dhar and Chiplunkar, 2010; Roodman
and Dougall, 2008). Aminobisphosphonates inhibit activity and survival
of osteoclasts (Caraglia et al., 2006). Besides their antitumor and anti-
resorptive ability, aminobisphosphonate (Zoledronic acid) are potent
activators of γδ T cells. IL6, dominantly secreted by “freshly isolated”
γδ T cells (low CD25, CD69 expression) promote osteoclastogenesis,
while antigen (BrHPP) activated γδ T cells (high CD25, CD69 expres-
sion) inhibit osteoclastogenesis through increased IFNγ production.
This data adds a newdimension towards understanding themechanism
of action of aminobisphosphonate in patients receiving this treatment
for skeletal metastasis. Although antitumor and anti-resorptive roles
of aminobisphosphonates are reported, the present study further
demonstrates the crosstalk of immune cells and osteoclasts mediated
by aminobisphosphonates. Future immunotherapeutic approaches can
utilize aminobisphosphonates activated γδ T cells for treatment of
skeletal metastasis.
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Effect of γδ T cells on osteoclastogenesis depends on their activation
status. Phosphoantigen “activated” γδ T cells express higher levels of ac-
tivation markers (CD25 and RANKL expression) and secrete higher
levels of IFNγ (anti-osteoclastogenic), thus inhibiting osteoclast genera-
tion and function. On the contrary, “freshly isolated” γδ T cells, in an
unstimulated state (low CD25, CD69 and RANKL expression) secrete
higher levels of IL6 (pro-osteoclastogenic) and enhance osteoclast gen-
eration and function. “Freshly isolated” γδ T cells, when stimulatedwith
phosphoantigen (BrHPP) showed increased IFNγ secretion and attained
anti-osteoclastogenic potential. Neutralization of IFNγ and IL6 using
blocking antibodies majorly diminished the “inhibitory” or “stimulato-
ry” effect of “freshly isolated” and “activated” γδ T cells respectively
on osteoclastogenesis. In conclusion, activation status and dynamics of
IL6/IFNγ dictates pro or anti-osteoclastogenic role of γδ T cells.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bonr.2015.10.004.
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